Asymptomatic Carotid Artery Stenosis: Identification of Subgroups with Different Underlying Plaque Characteristics  by van Lammeren, G.W. et al.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 43 (2012) 632e636Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comAsymptomatic Carotid Artery Stenosis: Identiﬁcation of Subgroups with
Different Underlying Plaque Characteristics
G.W. van Lammeren a,b,e, A.G. den Hartog a,e, G. Pasterkamp b, A. Vink c, J.-P.P.M. de Vries d,
F.L. Moll a, G.J. de Borst a,*
aDepartment of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
b Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands
cDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
dDepartment of Vascular Surgery, St Antonius Hospital, Nieuwegein, The Netherlands
WHAT THIS PAPER ADDS
 The current study shows that subgroups of patients with asymptomatic carotid artery stenosis with different plaque characteristics
can be identiﬁed based on reported past ipsilateral events. Patients who suffered from an ipsilateral event longer than 6 months
before carotid endarterectomy (CEA) are currently classiﬁed as asymptomatic, but have a relatively unstable plaque composition
compared with patients who never experienced ipsilateral events. This ﬁnding might contribute to improved understanding of
asymptomatic carotid artery stenosis and future stroke risks in subgroups, which might result in adjusted future treatment
strategies for subgroups.a r t i c l e i n f o
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Objectives: Optimal surgical treatment of patients with asymptomatic carotid artery stenosis (ACAS)
remains a matter of debate. Established deﬁnitions of ACAS include: (1) patients who never suffered from
ipsilateral cerebrovascular events (group 1) or (2) patients who suffered from ipsilateral cerebrovascular
events more than 6 months prior to revascularisation (group 2). Cerebrovascular symptoms are closely
related to underlying carotid plaque composition and therefore we investigated potential plaque
differences between these deﬁnition-based subgroups.
Design: Cross-sectional analysis of a longitudinal prospective biobank study.
Material and methods: Carotid atherosclerotic plaques from 264 asymptomatic patients were harvested
during endarterectomy, and subjected to histopathological examination. Patients were divided into two
groups: group 1: truly asymptomatic (n ¼ 182), and group 2: patients with ipsilateral events more than 6
months before carotid endarterectomy (CEA) (n ¼ 82).
Results: Patients in group 1 had relatively more stable plaque characteristics as compared with patients in
group 2, with a higher median plaque smooth muscle cell content (2.1 (0.0e18.7) vs. 1.6 (0.0e14.4);
P ¼ 0.036), a higher proportion of heavily calciﬁed plaques (67.7% (123/182) vs. 48.8% (40/82);
P ¼ 0.005) and less frequently intraplaque haemorrhages (11.5% (21/182) vs. 30.5% (25/82); P ¼ 0.001).
Conclusion: Different plaque characteristics within subgroups of ACAS patients can be identiﬁed based on
reported past ipsilateral events, which might result in adjusted future treatment strategies.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tions on this paper, please go
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ciety for Vascular Surgery. PublishThe prevalence of severe asymptomatic carotid artery stenosis
(ACAS) in the general population ranges from 0% to 3%.1 The annual
stroke rate in patients with ACAS varies from 1% up to 3%.2e4
Several large clinical trials investigated the optimal treatment in
patients with ACAS, and focussed on best medical treatment (BMT)ed by Elsevier Ltd. All rights reserved.
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artery stenting (CAS), but results of these trials are conﬂicting.5e8
There is level one evidence that CEA is beneﬁcial compared to
medical therapy.6,7 Recently, Asymptomatic Carotid Surgery Trial
(ACST-1) concluded that compared to BMT, successful CEA for
asymptomatic patients younger than 75 years signiﬁcantly reduces
10-year stroke risks.9 However, despite this evidence, revascular-
isation of ACAS remains a matter of debate. The majority of the
criticism is founded on the fact that BMT is still improving, and not
all patients in the medical arm of the conducted large randomised
trials did receive this treatment uniformly.10e12 In addition, the
absolute risk reduction of CEA is relatively small.11,12 The number
needed to treat (NNT) of 32 to prevent one disabling stroke over
a 5-year follow-up period, and a NNTof 20 over a 10-year follow-up
period in patients under the age 75 years,6,9 have to be taken into
account and must outweigh the procedural related risks. This
relatively high NNT can, in part, be explained by the underlying
carotid plaque composition and morphology. In symptomatic
patients, plaque composition is strongly associated with presenting
symptoms and have relatively unstable, ruptured or rupture-prone
plaques.13,14 For symptomatic patients with severe carotid stenosis
(70e99%), North American Symptomatic Carotid Endarterectomy
Trial (NASCET) has reported a cumulative risk of any ipsilateral
stroke of 26% for those treated medically.15 In European Carotid
Surgery Trial (ECST), the 3-year risk of stroke was 16.8% for those
patients randomised to medical therapy.16 In comparison, asymp-
tomatic patients have relatively stable carotid plaque features with
low risk for plaque rupture and subsequent cerebrovascular events.
Nevertheless, a proportion of 1e3% within the domain of asymp-
tomatic patients on BMTannually suffers from ipsilateral stroke.2e4
Therefore, stratiﬁcation of patients at risk for future stroke, and
who might have a higher beneﬁt of revascularisation is warranted.
Assumptions about identiﬁcation of subgroups with a higher stroke
risk within asymptomatic patients have been made.11 In several
trials and guidelines, patients were considered asymptomatic if (1)
patients did not have any ipsilateral symptoms in history or (2)
patients with ACAS, but with any ipsilateral symptoms of the
carotid territory longer than 6 months ago.8,17,18 Due to the strong
association between the index event, and underlying plaque
composition in symptomatic patients, we hypothesised that carotid
plaque features could also differ between these ACAS subgroups.
Materials and Methods
Patient population
Athero-Express is an ongoing biobank study, collecting carotid
plaques harvested during CEA. Medical ethics boards of the two
participating tertiary referral hospitals (University Medical Center
Utrecht and St. Antonius Hospital Nieuwegein, The Netherlands)
approved the study. Between 2002 and 2010, 264 asymptomatic
patients could be identiﬁed for the current study. All included
patients provided written informed consent. First, these patients
were screened by a neurologist and a vascular surgeon. Second,
computed tomography of their brain did not show fresh ischaemic
lesions. Indications for CEA were reviewed by a multidisciplinary
team and based on recommendations by the Asymptomatic Carotid
Atherosclerosis Study and Asymptomatic Carotid Surgery Trial
studies.6,7 Asymptomatic restenotic lesions were excluded from the
current study. Preoperative carotid artery ﬂow velocity and degree
of stenosis were assessed with duplex ultrasound, and interpreted
according to the modiﬁed Strandness criteria.19 Participating
patients ﬁlled out an extensive questionnaire including general
medical history, cardiovascular morbidity, medication use and
cardiovascular risk factors. Missing data from the questionnaireswere completed with information from admission charts, or the
general practitioner was contacted. Patients were considered
smokers if they reported to be smoking or did not quit smoking
until the year of surgery. Diabetic status was restricted to those
patients receiving medical treatment including insulin or oral
glucose-lowering drugs. Hypertension was deﬁned as the use of
antihypertensive drugs. Coronary artery disease (CAD) was deﬁned
as a history of myocardial infarction, percutaneous transluminal
coronary angioplasty, coronary artery bypass grafting or coronary
artery stenosis reported from angiograms. Peripheral arterial
disease (PAD) was deﬁned as (intermittent) claudication with an
ankle-brachial index <0.7, or a history of peripheral artery surgery
including femoral thrombo-endarterectomy, or bypass surgery.
Deﬁnitions of study groups
All asymptomatic patients were divided into two groups based
on the deﬁnitions reported in previous studies. The ﬁrst group was
deﬁned as patients who did not have any ipsilateral symptoms in
history, and will also be referred to as truly asymptomatic patients
(group 1). The second groupwas deﬁned as patients with ipsilateral
symptoms of the carotid artery territory, but longer than 6 months
prior to CEA (group 2).8,17,18
Atherosclerotic plaque assessment
Atherosclerotic plaques of patients were harvested during CEA
according to a standardised and previously reported protocol.20,21
In short, the carotid plaque was divided into segments of 5 mm
thickness. The sectionwith the largest plaque burdenwas classiﬁed
as culprit lesion and subjected to immunohistochemical staining.
Plaqueswere stained formacrophages (CD 68), smoothmuscle cells
((SMCs), alpha-actin), collagen (Picro-sirius Red (PSR)), calciﬁca-
tions (haematoxylin eosin (H&E)), lipid cores (H&E and PSR),
microvessels (CD34) and luminal thrombi or intraplaque
haemorrhages (H&E and ﬁbrin (Mallory’s phosphotungstic acid-
haematoxylin)).20e22 Macrophage content and SMC content
were analysed digitally with Analysis software (AnalySIS 3.2, Soft
Imaging Systems GmbH, Münster, Germany). Based on colour
thresholds, the software computed the percentage of the plaque
that was positive for: CD68 for macrophages, and a-actin for SMC
content, respectively. Microvessels in the plaque were scored in
three hot spots and reported as an average number of vessels per
hot spot.22 In addition, collagen and calciﬁcations were scored
semi-quantitatively as no/minor or moderate/heavy staining,
according to the following criteria: (1) no or minor staining along
part of the luminal border of the plaque or a few scattered spots
within the lesion and (2) moderate or heavy staining along the
entire luminal border or evident parts within the lesion. Size of the
lipid core was visually assessed and cut off at 40%, based on the
association with rupture-prone plaques.23 Luminal thrombus was
deﬁned as a solid mass formed from ﬁbrin and platelets super-
imposed on the plaque, within the vascular lumen.24 Loose eryth-
rocytes in the lumen were scored negative for luminal thrombi.
Intraplaque haemorrhage was deﬁned as a haemorrhagewithin the
atherosclerotic plaquewithout signs of cap rupture.24 Intraobserver
and interobserver variability of the histological assessment were
examined previously and reproducibility was found to be good (k
0.6e0.9).20
Clinical outcome
We investigated the clinical outcome after CEA for both study
groups. End points were deﬁned as described previously.21,22
Primary end point was a composite of all cardiovascular end
Table 1
Baseline characteristics among the two groups with asymptomatic carotid stenosis.
Clinical baseline parameter Truly asymptomatic
N ¼ 182
Symptomatic >
6 months prior to
CEA N ¼ 82
P value
Gender, male 139 (76.4) 63 (76.8) 0.936
Age, years 65.9  9.1 66.8  9.5 0.473
Diabetes mellitus 37 (20.8) 17 (20.7) 0.992
Current smoker 49 (28.5) 25 (31.3) 0.654
Hypertension 155 (89.6) 68 (84.0) 0.200
Body mass index (kg/m2) 26.7  3.5 26.6  3.2 0.877
eGFR (ml/min/1.73m2) 68.9  19.6 70.9  19.4 0.471
Coronary artery disease 59 (33.9) 15 (18.5) 0.012
Peripheral artery disease 47 (26.6) 12 (14.8) 0.037
Statin use 140 (79.5) 56 (68.3) 0.049
Aspirin use 153 (86.9) 72 (87.8) 0.845
Oral anticoagulants use 21 (11.9) 10 (12.2) 0.952
Baseline characteristics presented absolute numbers (percentage) or as
means  standard deviation.
Abbreviations: CEA, carotid endarterectomy; eGFR, estimated glomerular ﬁltration
rate.
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infarction, coronary interventions and peripheral vascular inter-
ventions) and cardiovascular mortality (fatal stroke, fatal MI and
fatal abdominal aortic aneurysm (AAA)erupture). Secondary end
points were major cardiovascular events (stroke, myocardial
infarction or cardiovascular-related death). We additionally studied
stroke and myocardial infarction as separate end points. The end-
point stroke contains all strokes (ipsilateral and contralateral)
during follow-up.
Statistical analyses
Statistical Package for the Social Sciences (SPSS) version 17.0
(SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.
Baseline differences between the two groups of asymptomatic
patients and differences in histological plaque parameters were
examined with Pearson Chi-square test for binominal variables,
and Student’s t-test for continuous variables. If continuous vari-
ables showed a non-linear distribution, logarithmic transformation
was applied where appropriate. The continuous data of macro-
phages, SMC and plaque microvessel density were non-parametric
and were therefore logarithmically transformed and reported as
‘log macrophages’, ‘log smooth muscle cells’ and ‘log microvessels’
in the tables, and additionally as original data in the manuscript as
a reference. To assess the independent association between plaque
characteristics and the two groups and thereby correct for baseline
differences and potential confounders that showed an associationTable 2
Histological parameters and associations with two groups with asymptomatic carotid st
Continuous histological
parameters
Truly asymptomatic
N ¼ 182
Symptomatic
prior to CEA
Log macrophages 0.55  0.79 0.51  0.79
Log smooth muscle cells 0.19  0.57 0.01  0.80
Log microvessels 0.86  0.38 0.90  0.22
Binominal histological
parameters
Truly asymptomatic
N ¼ 182
Symptomatic
prior to CEA
Lipid core > 40% of plaque surface 37 (20.3) 25 (30.5)
Moderate/heavy calciﬁcations 123 (67.6) 40 (48.8)
Moderate/heavy collagen 157 (86.3) 61 (74.4)
Intraplaque hemorrhage 21 (11.5) 25 (30.5)
Luminal thrombus 86 (47.3) 35 (42.7)
Plaque parameters presented as means  standard deviation, or absolute numbers (per
ratio.
a adjusted for coronary artery disease, peripheral artery disease, and preoperative stawith the two groups with a P-value < 0.20, multiple linear and
logistic regression models were conducted for continuous and
binary variables, respectively. Differences in clinical outcome
between groups were assessed with Cox regression survival
analyses.
Results
Patients
Of all 264 patients, 182 (68.9%) were truly asymptomatic and
never suffered from ipsilateral cerebrovascular events (group 1),
and 82 (31.1%) had suffered from ipsilateral symptoms but longer
than 6months before CEA (group 2). The indications for CEA in both
groups included multivessel disease involving at least three
extracranial arteries with stenosis >70% in combination with
a progressive ipsilateral stenosis, bilateral stenosis with an
incomplete circle of Willis or a symptomatic contralateral occlu-
sion. The events that occurred in the 82 patients that were symp-
tomatic, but had their index event more than 6 months before CEA,
encompassed transient ischaemic attack (n ¼ 40), amaurosis fugax
(n ¼ 15), minor stroke (n ¼ 12), stroke (n ¼ 9), retinal infarction
(n ¼ 3) and aspeciﬁc haemodynamic complaints (n ¼ 3). The
median time (interquartile range (IQR)) between the index event
and surgery in this group was 237 (207-335) days.
Baseline differences between the two groups encompassed
a higher prevalence of systemic atherosclerotic disease, including
CAD and PAD among the truly asymptomatic patients, who never
suffered from an ipsilateral event (Table 1). In addition, truly
asymptomatic patients were on statins before surgery more
frequently (Table 1).
Carotid plaque characteristics
SMC content in group 1 was higher with a median of 2.1
(0.0e18.7) compared with a median of 1.6 (0.0e14.4) in group 2
(adjusted P ¼ 0.036) (Table 2). In group 1, 123 carotid plaques
(67.7%) showed signs of moderate to heavy carotid plaque calciﬁ-
cations, compared with 40 plaques (48.8%) from group 2 (adjusted
P ¼ 0.005). The adjusted odds ratio (OR) for moderate or heavy
plaque calciﬁcations in this group was 0.453 (0.260e0.788)
(Table 2). In addition, intraplaque haemorrhage was present in 21
plaques (11.5%) from patients in group 1 versus 25 plaques (30.5%)
from group 2 (adjusted P¼ 0.001). The adjusted OR for the presence
of intraplaque haemorrhage for patients in group 2 was 3.351
(1.686e6.661) (adjusted P ¼ 0.001) (Table 2). Univariate analyses
also showed a possible association with plaque collagen content,enosis.
> 6 months
N ¼ 82
Univariate
P value
Adjusted
coefﬁcient (SE)a
Adjusted
P valuea
0.714 0.016 (0.109) 0.886
0.023 0.195 (0.093) 0.036
0.356 0.025 (0.052) 0.630
> 6 months
N ¼ 82
Univariate
P value
Adjusted OR
[95% CI]a
Adjusted
P valuea
0.072 1.542 [0.837e2.841] 0.165
0.004 0.453 [0.260e0.788] 0.005
0.019 0.547 [0.280e1.069] 0.078
<0.001 3.351 [1.686e6.661] 0.001
0.490 0.724 [0.414e1.266] 0.257
centage). Abbreviations: CEA, carotid endarterectomy; SE, standard error; OR, odds
tin use with multivariable linear, and logistic regression analyses.
Table 3
Clinical outcome after carotid endarterectomy.
Endpoint Truly asymptomatic
(N ¼ 182)
Symptomatic >6 months
prior to CEA (N ¼ 82)
P valuea Odds ratio [95% CI]b
Composite endpoint 26.4% (48/182) 20.7% (17/82) 0.203 0.689 [0.401e1.214]
Major cardiovascular end point 8.2% (15/182) 7.3% (6/82) 0.684 0.882 [0.389e2.119]
Stroke 4.4% (8/182) 3.7% (3/82) 0.719 0.784 [0.208e2.957]
Myocardial infarction 2.2% (4/182) 3.7% (3/82) 0.585 1.519 [0.339e0.698]
a Calculated with Cox regression analyses.
b Represents the risk of an event for patients who were symptomatic >6 months prior to CEA (group 2), as compared with truly asymptomatic patients (group 1). Events
include endpoints within and after 30 days.
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signiﬁcant difference remained. No differences between the patient
groups were observed for macrophages, microvessels, lipid core
size or luminal thrombi.
Clinical outcome
During a mean follow-up of 2.35 (1.0) years, no statistical
differences in event rates were observed (Table 3). Cardiovascular
outcome after CEA was therefore comparable between groups.
Discussion
With the current analysis, we have shown that patients who
suffered from ipsilateral cerebrovascular symptoms, but underwent
CEA longer than 6 months after the index event, have different
plaque characteristics than patients who never experienced ipsi-
lateral symptoms. Patients who were truly asymptomatic had
a higher overall plaque SMC content, a higher prevalence of heavily
calciﬁed plaques and a lower prevalence of intraplaque haemor-
rhages. To the best of our knowledge, this is the ﬁrst study that
describes the association between plaque characteristics and two
subgroups based on applied deﬁnitions for ACAS.
We also observed a tendency towards decreased plaque collagen
content in group 2, and thus amore vulnerable plaque composition.
This tendency is in line with previous ﬁndings, describing that
a decline in SMC content is accompanied by a decrease in synthesis
of collagen type I and III, resulting in weakening of the ﬁbrous cap
overlying the plaque which eventually leads to an increased
risk of plaque rupture.25 However, after correction for potential
confounders through multivariable logistic regression, the differ-
ence in plaque collagen content between the two groups was not
statistically signiﬁcant. The ﬁnding that plaque calciﬁcations were
more frequently present in plaques from truly asymptomatic
patients (group 1) might indicate a more stable underlying plaque
composition. Plaque calciﬁcations are considered to be potentially
stabilising and are associated with a more ﬁbrous and stable plaque
composition.26 This is in line with previous ﬁndings from Nandalur
and colleagues who have shown that the proportion of carotid
plaque calciﬁcation, rather than absolute plaque volume, is asso-
ciated with stability and asymptomatic status.27 Unfortunately, no
study on stroke risk and histological plaque features has been
performed until date. Rothwell et al. described a stroke risk model,
including morphological plaque surface features detected with
angiography, rather than cellular plaque components such as SMCs
plaque haemorrhage and calciﬁcations.28 Future imaging studies
with asymptomatic patients on BMT will have to investigate
potential associations between plaque composition and stroke risk.
Furthermore, patients in group 2 had a higher prevalence of
intraplaque haemorrhages compared with truly asymptomatic
patients. The presence of intraplaque haemorrhage inside carotid
plaques is considered to be an important vulnerable plaquecharacteristic, since plaque haemorrhages contribute to athero-
sclerotic plaque progression and increased risk of plaque rupture,
and consequently ipsilateral events.25,26,29,30 In addition, carotid
plaque haemorrhages are also associated with systemic cardio-
vascular events after CEA.22 In the current cohort, however, we did
not observe statistical differences in systemic cardiovascular
outcome after CEA between groups. Overall, it might be conceivable
that patients on BMT who have never experienced any ipsilateral
symptoms are less likely to develop a future ipsilateral event due to
their more stable underlying plaque composition including more
SMCs, more calciﬁcations and less intraplaque haemorrhages,
compared with patients who did have ipsilateral symptoms but
more than 6 months prior to CEA.
The fact that no differences in plaque inﬂammation could be
observed can be ascribed to plaque stabilisation after cerebrovas-
cular events.31,32 Shortly after plaque rupture, macrophages enter
the plaque. However, over time the plaque macrophage and
inﬂammatory protein content gradually decreases. This might
explain why we did not observe a difference between the two
groups of ACAS patients.
Analyses of carotid plaque rupture were not conducted in our
study, due to disruption of plaque morphology caused by surgical
trauma.20 This makes interpretation of cap rupture rather difﬁcult,
which is in line with ﬁndings from Lovett et al., who stated that
reproducibility of histological assessment of plaque rupture is
limited.33 Possible confounding factors in the current study might
be sought in baseline differences between the groups and include
CAD, PAD and statin use. Nevertheless, we corrected for these
factors in multiple regression analyses and therefore expect that
the observed differences are accurate.
Future perspectives
The current study might contribute to improved understanding
of ACAS and underlying plaque composition in subgroups. Patients
who suffered from an ipsilateral event longer than 6 months before
CEA are currently classiﬁed as asymptomatic, but have a relatively
unstable plaque composition compared with patients who never
experienced ipsilateral events. This suggests that patients with past
events might have different long-term ipsilateral stroke risks. This
hypothesis will have to be conﬁrmed with data from randomised
trials focussing on ACAS. Furthermore, it would be of interest to
investigate whether our ﬁndings on plaque composition can be
conﬁrmed with plaque-imaging studies in asymptomatic patients.
The current study might thus provide new insights for stratiﬁcation
of subgroups, and adjusted future treatment strategies for patients
with ACAS.
Conclusion
Within the domain of patients with ACAS, individuals that never
suffered from ipsilateral symptoms have a higher plaque SMC
G.W. van Lammeren et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 632e636636content, higher prevalence of heavy plaque calciﬁcations and lower
prevalence of intraplaque haemorrhage, comparedwith individuals
who suffered from an event more than 6 months prior to surgery.
This implies that subgroups within ACAS patients can be identiﬁed
based on reported past ipsilateral events, which might result in
adjusted future treatment strategies for these speciﬁc subgroups.
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